We’ve come a long way since tissue biopsies were considered the go-to way to obtain samples needed to test for cancer. Breast cancer, prostate cancer, and lung cancer all required invasive methods to obtain tissue. Thankfully, liquid biopsies–whether through...
The OncobiotaLUNGdetect is a multi-species, multi-omic liquid biopsy assay that will aid clinicians in risk stratification of pulmonary nodules. Micronoma is the first company to commercialize an assay that integrates metagenomic, proteomic, clinical and radiomic...
Jerry started working for Micronoma in May 2023. He was born in China, and raised in San Francisco, where he also went to college (California State, East Bay). As a Senior Scientist, Jerry is part of the computational biology team responsible for data analysis and...
This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.– Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of...
Nick started working for Micronoma in February 2023. He was born and raised in San Diego, and went to college at UC Davis. As a Customer Care Manager, Nick’s main goal is to create a white glove customer experience at Micronoma. He is responsible for building our...
Up to two million incidentally detected pulmonary nodules (IPN) appear each year onimages coming from diagnostic scans that patients undergo for reasons unrelated tolung cancer. These nodules are abnormal growths (neoplasms) that form in the lungand, upon...
